In many parts of the world, scabies is dismissed as an irritating but minor skin complaint—an itch treated with a cream and quickly forgotten. Across the South Pacific, however, clinicians and public health officials describe something very different: a highly prevalent parasitic infection that spreads rapidly in crowded households, fuels bacterial skin disease and, in its most severe forms, can become life-threatening. In response, island nations including the Solomon Islands and Fiji have helped pioneer an approach more often associated with malaria or neglected tropical diseases: treating entire communities at once.
Scabies is caused by the microscopic mite Sarcoptes scabiei, which burrows into the skin and triggers intense itching and a rash. Transmission typically requires prolonged skin-to-skin contact, meaning it thrives where people sleep close together and where housing is crowded—conditions common in many Pacific settings because of large extended families, limited housing stock and the high cost of building materials.
Researchers studying South Pacific communities have repeatedly reported some of the highest scabies burdens recorded anywhere. Surveys in multiple island settings have found that children carry a disproportionate share of infections, with some communities seeing scabies as a near-universal childhood experience. Health workers say the disease often becomes normalised: families expect cycles of itching, scratching and re-infection, and clinics are overwhelmed by repeat presentations.
The consequences go beyond discomfort. Scratching breaks the skin barrier, allowing bacteria—particularly group A streptococcus and Staphylococcus aureus—to invade. Studies in the region and elsewhere have linked scabies control to reductions in impetigo (a common bacterial skin infection) and to downstream risks such as invasive bacterial infection and post-streptococcal complications. Medical specialists in Pacific hospitals have long warned that the “itch” can be a gateway to serious illness, especially for infants, older adults and those with chronic disease.
These realities have driven a shift from individual treatment to mass drug administration (MDA): offering medication to everyone in a defined population, regardless of symptoms, to stop transmission and break the cycle of reinfection. In Fiji and the Solomon Islands, programmes have trialled community-wide treatment using oral ivermectin, an antiparasitic medicine also used for other neglected tropical diseases. Where ivermectin is unsuitable—such as for very young children or pregnant women—topical therapies can be substituted, with treatment strategies adjusted to local clinical guidelines.
Evidence from field studies suggests that well-run MDA can sharply reduce scabies prevalence and also lower rates of bacterial skin infection. Public health teams report that the largest gains are seen when high coverage is achieved and when follow-up dosing is delivered on schedule—because mites and newly hatched larvae must be targeted in successive treatment rounds. Researchers emphasise that the approach works best when it is community-led, with trusted local health workers explaining the rationale and addressing concerns about taking medication when a person feels well.
Operational hurdles remain. Many outer islands and remote villages can only be reached by boat or small aircraft, and drug distribution must contend with weather, fuel costs and fragile supply chains. Achieving high participation can be difficult in places where populations are mobile for work, education or family obligations. There are also clinical complexities: “crusted scabies,” a severe form that can carry enormous mite loads, requires intensive management and can seed ongoing community transmission if not identified and treated. Health authorities therefore stress the importance of training for frontline staff, robust referral pathways and surveillance systems that can detect resurgences.
Experts involved in Pacific skin health efforts argue that scabies control should not sit in isolation. They describe a broader package: improving access to diagnosis and treatment at primary care level; integrating scabies into child health and school health services; strengthening water, sanitation and hygiene messaging; and addressing overcrowded housing, the underlying driver that allows scabies to spread so efficiently. In this view, MDA is an accelerant—a way to rapidly reduce disease while longer-term investments catch up.
Internationally, scabies has gained recognition as a significant public health problem, with growing calls to expand scalable control programmes in high-burden settings. Pacific experiences are frequently cited by researchers as proof that scabies is not an inevitable fact of life in tropical communities—and that decisive, population-level interventions can deliver measurable benefits.
For Fiji, the Solomon Islands and their neighbours, the stakes are both medical and social. Itching that keeps children awake can disrupt school attendance. Visible skin disease can bring stigma. And recurrent bacterial infections add to healthcare costs in systems that already operate with limited specialist capacity. By using mass treatment to interrupt transmission, Pacific programmes are attempting something ambitious: turning a ubiquitous childhood affliction into a preventable—and potentially eliminable—community disease.
Why it matters
Scabies is more than an itch: in high-burden settings it contributes to bacterial infections that can lead to severe illness and long-term complications. The South Pacific’s experience with mass drug administration is shaping how global health agencies think about controlling a neglected disease at scale. If sustained and paired with housing and primary care improvements, these programmes could offer a replicable model for other regions where scabies remains entrenched.